Table 3 Risk factors for MPP with adenovirus coinfection
Characteristics | With adenovirus coinfection (n = 24) | Without adenovirus coinfection (n = 83) | P value |
|---|---|---|---|
Age (y) | 3.362 ± 2.590 | 4.531 ± 3.440 | 0.078 |
Gender (male/female) | 13/11 | 42/41 | 0.819 |
Clinical presentation | |||
 Wheezing, No. (%) | 10(41.67) | 10(12.05) | 0.002 |
 Hypoxemia, No. (%) | 6(25.00) | 10(12.05) | 0.189 |
 Extrapulmonary complications, No. (%) | 9(37.50) | 10(12.05) | 0.012 |
 Duration of fever (d) | 12.083 ± 9.343 | 6.422 ± 3.357 | 0.007 |
 Duration of wheezing (d) | 0.00(0.00,8.00) | 0.00(0.00,5.00) | 0.570 |
 Fever longer than 7 days, No. (%) | 20(83.33) | 36(43.37) | 0.001 |
Imaging features | |||
 Consolidation, No. (%) | 19(79.17) | 40(48.19) | 0.010 |
 Interstitial changes, No. (%) | 5(20.83) | 37(44.58) | 0.056 |
Laboratory tests | |||
 White blood cell count (*109/L) | 9.003 ± 3.487 | 8.966 ± 3.496 | 0.964 |
 Lymphocyte percentage (%) | 36.488 ± 14.274 | 34.153 ± 15.106 | 0.491 |
 C-reactive protein (mg/l) | 10.00(4.00,25.00) | 12.00(7.25,25.00) | 0.997 |
 A2063G mutation, No. (%) | 9(37.50) | 51(61.45) | 0.060 |
Treatment | |||
 No fever within 48 h after application of macrolides, No. (%) | 5(20.83) | 26(31.33) | 0.445 |
 Application of glucocorticoids, No. (%) | 17(70.83) | 51(61.45) | 0.476 |
 Mechanical ventilation, No. (%) | 1(4.17) | 6(7.23) | 1 |